Quantcast

Latest Bupivacaine Stories

2014-06-19 23:09:27

On June 18, the FDA published a voluntary recall for one lot of Marcaine (Bupivacaine HCI Injection, USP), 0.5 percent, 30 ML, Single-Dose, Preservative-Free, by Hospira, due to visible particulates. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) June 19, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on...

2014-05-16 08:26:43

CUPERTINO, Calif., May 16, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR((TM)) (SABER(®)-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the International Anesthetic Research Society (IARS) Annual Meeting. The meeting will be held on May 17-20 at the Fairmont Queen Elizabeth Hotel in Montreal. "Bupivacaine is a widely used local anesthetic...

2014-04-30 23:25:36

As the FDA announced on April 22, one lot of 0.25% Marcaine (Bupivacaine HCl Injection, USP), 10 mL, single-dose vial, preservative free, is recalled due to visible particulates in the vial. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) April 29, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety...

2014-04-30 08:33:52

ON-Q's ability to adapt to changing pain relief needs over the first five days following surgery provides significant benefits for patients and providers IRVINE, Calif., April 30, 2014 /PRNewswire/ -- I-Flow LLC, a Kimberly-Clark Health Care Company and manufacturer of the ON-Q Pain Relief System (ON-Q), today announced the full findings of a Frost & Sullivan white paper documenting clinician perspective that ON-Q delivers superior pain control over the full length of the postoperative...

2014-04-01 16:25:48

CUPERTINO, Calif., April 1, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that data for POSIDUR((TM)) (SABER(®)-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia, is being presented at the 39(th) Annual American Society of Regional Anesthetic and Pain Medicine Meeting. The meeting will be held on April 3-6 at the Sheraton Chicago Hotel and Towers in Chicago....

2014-02-12 16:27:03

Company will Host Conference Call on February 13, 2014 CUPERTINO, Calif., Feb. 12, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for POSIDUR((TM)) (SABER(®)-Bupivacaine), an investigational drug for administration into the surgical site to produce post-surgical analgesia. Based on its review, the FDA has determined that they cannot approve the NDA in its present form,...

2012-11-12 11:55:40

A randomized, double-blind clinical trial by researchers at Hospital for Special Surgery has revealed that corticosteroids are more effective than the more expensive treatment, hylan G-F 20 (Synvisc One, Genzyme Biosurgery), in providing pain relief to patients with thumb arthritis. The study also showed that both of these commonly used treatments provided clinically meaningful pain relief, but so did a placebo injection. "On average, each of the therapies resulted in clinically meaningful...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related